Citations

Showing 10 of 108083 citations.

Part II: Interactive case—Clinical pearls of clozapine
Leung, Jonathan G. , Leung, Jonathan G

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | March 10, 2023 | Volume: 6 | Issue: 3 | Pages: 312-318

10.1002/jac5.1765 Get It

Sex-Specific Thresholds for Cardiac Biomarkers—We Need to Move Forward
Lobo, Ronstan , Jaffe, Allan S. , Jaffe, Allan S.

Mayo Clinic

Reviews in Cardiovascular Medicine | March 10, 2023 | Volume: 24 | Issue: 3 | Pages: No page available

10.31083/j.rcm2403086 | PMID 39077486 Get It

Cardiovascular biomarkers play a major diagnostic role for cardiologists. Different biomarkers provide different insights into a variety of cardiovascular conditions and in doing so they improve diagnosis and management. Often, these biomarkers are deployed without carefully evaluating the use of sex-specific cut off values. It is now becoming apparent that the use of such cut off values can improve prognostication and discrimination in some clinical situations. This review paper will focus on the data indicating that there is benefit to the use of sex-specific thresholds. It should be clear that these thresholds will vary depending on the analyte being measured and the specific clinical indication for which the patients are being evaluated; and sex-specific cut off values may be important in some situations but not others. Nonetheless, it is now clear that when evaluating sex-specific cut off values, one often finds benefit. We will highlight these situations using specific cardiac biomarkers as examples.
Alemtuzumab-Induced Thyroid Eye Disease: A Comprehensive Case Series and Review of the Literature
Nirmalan, Aravindh, Blecher, Nathanael, Hyder, Sayyada, Couch, Steven M., Godfrey, Kyle J. , Wagner, Lilly H. , Tooley, Andrea A. , Stan, Marius N. , Bradley, Elizabeth A.

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | March 9, 2023 | Volume: 39 | Issue: 5 | Pages: 470-474

10.1097/iop.0000000000002367 | PMID 36893061 Get It

Purpose: To present 5 cases of alemtuzumab-induced thyroid eye disease (AI-TED) and review the literature to highlight the natural history, severity, and outcomes as compared with conventional thyroid eye disease (TED). Methods: A multi-institutional retrospective case series of patients with AI-TED was compiled. Chart review evaluated for clinical characteristics, imaging findings, and treatment for AI-TED. Additionally, a comprehensive review of the literature identified all previously published cases of AI-TED. Results: Five new patients with AI-TED were included in this series. The average clinical activity score on presentation was 2.8 (range 1–4) and reached an average peak of 5.0 during the active phase of the disease (4–7). Patients were treated medically with selenium (40%) or monoclonal antibodies including teprotumumab or tocilizumab (40%). Surgical treatment with orbital decompression for compressive optic neuropathy was performed on 2 (40%) patients. Combined with 11 previously reported cases, these 16 patients with AI-TED had an average clinical activity score on presentation of 3.3. The average length of the AI-TED phase was 14.0 months, and all patients were treated with medical and/or surgical interventions for their disease. Conclusions: Clinical and imaging findings in AI-TED mirror that of conventional TED, however, AI-TED may present with greater severity. AI-TED may develop many months after Graves’ disease; therefore, providers should be aware of this association and monitor patients for the development of severe TED.
Marked Hypoleptinemia Precedes Overt Fat Loss in Immune Checkpoint Inhibitor-induced Acquired Generalized Lipodystrophy
Dhanasekaran, Maheswaran , Sandooja, Rashi , Higgins, Alexandra S, Simha, Vinaya

Mayo Clinic

JCEM Case Reports | March 9, 2023 | Volume: 1 | Issue: 2 | Pages: No page available

10.1210/jcemcr/luad025 | PMID 37908472 Get It

Abstract Immune checkpoint inhibitors (ICIs) targeting cancer cells that evade immune T-cell regulation have revolutionized the treatment of metastatic carcinomas. Unfortunately, secondary endocrinopathies associated with ICI, including adrenal insufficiency, primary hypothyroidism, autoimmune diabetes, and rarely hypoparathyroidism, are increasing. Lipodystrophy, presumably due to the autoimmune destruction of adipocytes, leading to metabolic complications, is a less recognized adverse effect of ICI therapy. We present a case of a 66-year-old Caucasian woman treated with pembrolizumab, an anti-programmed death 1 inhibitor, for metastatic lung adenocarcinoma. Fifteen months after the treatment initiation, she was found to have hyperglycemia, hyperlipidemia, and hepatic steatosis but without any evidence of autoimmune diabetes. She was also noted to have isolated buccal fat pad loss, raising suspicion of acquired lipodystrophy. Despite well-preserved subcutaneous fat over the trunk and limbs, she had undetectable serum leptin levels. Whole-body fluorodeoxyglucose (FDG)-positron emission tomography scan showed diffuse mild FDG activity throughout the subcutaneous tissue, suggesting underlying inflammation. Over the next 3 months, she developed progressive fat loss leading to generalized lipodystrophy. Adipose tissue dysfunction, secondary to ICI-induced subclinical panniculitis, precedes overt fat loss and is characterized by hypoleptinemia and metabolic abnormalities.
Faculty Opinions recommendation of Comparison of labor analgesia efficacy between single-orifice and multiorifice wire-reinforced catheters during programmed intermittent epidural boluses: a randomized controlled clinical trial.
Sviggum, Hans P.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 9, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.742402310.793597921 Get It

Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer
Haddad, Tufia C. , D’Assoro, Antonino B. , Carter, Jodi M. , McMenomy, Brendan P., Santo, Katelyn, Karuturi, Meghan , Morikawa, Aki , Marcom, P. Kelly, Oh, Sun Young , Clark, Amy S. , Keyomarsi, Khandan , Hobday, Timothy J. , Peethambaram, Prema P. , O’Sullivan, Ciara C. , Leon‐Ferre, Roberto A. , Liu, Minetta C. , D'Assoro, Antonino B, O'Sullivan, Ciara C, Ingle, James N. , Carter, Jodi , Suman, Vera J. , Giridhar, Karthik V. , Mayer, Erica L. , Marcom, P. Kelly, Isaacs, Claudine , Mayer, Ingrid A. , Goetz, Matthew P.

Mayo Clinic

JAMA Oncology | March 9, 2023 | Volume: 9 | Issue: 6 | Pages: 815

10.1001/jamaoncol.2022.7949 | PMID 36892847 Get It

ImportanceAurora A kinase (AURKA) activation, related in part to AURKA amplification and variants, is associated with downregulation of estrogen receptor (ER) α expression, endocrine resistance, and implicated in cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) resistance. Alisertib, a selective AURKA inhibitor, upregulates ERα and restores endocrine sensitivity in preclinical metastatic breast cancer (MBC) models. The safety and preliminary efficacy of alisertib was demonstrated in early-phase trials; however, its activity in CDK 4/6i–resistant MBC is unknown.ObjectiveTo assess the effect of adding fulvestrant to alisertib on objective tumor response rates (ORRs) in endocrine-resistant MBC.Design, Setting, and ParticipantsThis phase 2 randomized clinical trial was conducted through the Translational Breast Cancer Research Consortium, which enrolled participants from July 2017 to November 2019. Postmenopausal women with endocrine-resistant, ERBB2 (formerly HER2)–negative MBC who were previously treated with fulvestrant were eligible. Stratification factors included prior treatment with CDK 4/6i, baseline metastatic tumor ERα level measurement (<10%, ≥10%), and primary or secondary endocrine resistance. Among 114 preregistered patients, 96 (84.2%) registered and 91 (79.8%) were evaluable for the primary end point. Data analysis began after January 10, 2022.InterventionsAlisertib, 50 mg, oral, daily on days 1 to 3, 8 to 10, and 15 to 17 of a 28-day cycle (arm 1) or alisertib same dose/schedule with standard-dose fulvestrant (arm 2).Main Outcomes and MeasuresImprovement in ORR in arm 2 of at least 20% greater than arm 1 when the expected ORR for arm 1 was 20%.ResultsAll 91 evaluable patients (mean [SD] age, 58.5 [11.3] years; 1 American Indian/Alaskan Native [1.1%], 2 Asian [2.2%], 6 Black/African American [6.6%], 5 Hispanic [5.5%], and 79 [86.8%] White individuals; arm 1, 46 [50.5%]; arm 2, 45 [49.5%]) had received prior treatment with CDK 4/6i. The ORR was 19.6%; (90% CI, 10.6%-31.7%) for arm 1 and 20.0% (90% CI, 10.9%-32.3%) for arm 2. In arm 1, the 24-week clinical benefit rate and median progression-free survival time were 41.3% (90% CI, 29.0%-54.5%) and 5.6 months (95% CI, 3.9-10.0), respectively, and in arm 2 they were 28.9% (90% CI, 18.0%-42.0%) and 5.4 months (95% CI, 3.9-7.8), respectively. The most common grade 3 or higher adverse events attributed to alisertib were neutropenia (41.8%) and anemia (13.2%). Reasons for discontinuing treatment were disease progression (arm 1, 38 [82.6%]; arm 2, 31 [68.9%]) and toxic effects or refusal (arm 1, 5 [10.9%]; arm 2, 12 [26.7%]).Conclusions and RelevanceThis randomized clinical trial found that adding fulvestrant to treatment with alisertib did not increase ORR or PFS; however, promising clinical activity was observed with alisertib monotherapy among patients with endocrine-resistant and CDK 4/6i–resistant MBC. The overall safety profile was tolerable.Trial RegistrationClinicalTrials.gov Identifier: NCT02860000
Open Achilles Tendon Repair
Moore, M. Lane , Pollock, Jordan R. , Karsen, Phillip J. , Haglin, Jack M. , Lai, Cara , Elahi, Muhammad Ali , Chhabra, Anikar , O’Malley, Martin , Patel, Karan A. , Lai, Cara H , Elahi, Muhammad A , Moore, M Lane , Patel, Karan , Pollock, Jordan Riley , Chhabra, Anikar

Mayo Clinic

JBJS Essential Surgical Techniques | March 9, 2023 | Volume: 13 | Issue: 1 | Pages: e21.00054

10.2106/jbjs.st.21.00054 | PMID 38274281 Get It

Background: An open Achilles tendon repair is performed in patients who have suffered an acute rupture. All patients with this injury should be counseled on their treatment options, which include open operative repair and functional rehabilitation. We prefer the use of an open repair in high-level athletes and those who have delayed presentation. Typically, this injury—and the resulting open repair—are seen in young or middle-aged patients as well as athletes. Operative repair of a ruptured Achilles tendon is associated with a much faster return to activity/sport when compared with nonoperative alternatives. This surgical procedure is especially useful in allowing this patient population to return to their previous activity level and functional capacity as quickly as possible. Description: Open repair of a ruptured Achilles tendon begins with a 6 to 8-cm incision over the posteromedial aspect of the lower leg. Superficial and deep dissections are performed until the 2 ends of the ruptured tendon are identified. Adhesions are debrided to adequately mobilize and define the proximal and distal segments of the tendon. With use of a fiber tape suture, a modified locking Bunnell stitch is utilized to secure both ends. The fiber tape is tied securely, and the repair is reinforced with Vicryl suture (Ethicon). Once the tendon is repaired, the paratenon layer is identified and repaired with a running 0 or 2-0 Vicryl suture. This is an important step to minimize postoperative wound complications. The wound is then closed, and the extremity is splinted in maximum plantar flexion. Alternatives: Alternative treatments include minimally invasive surgical techniques such as percutaneous Achilles tendon repair and nonoperative treatment with functional rehabilitation, which can provide excellent outcomes but can also lead to a slight decrease in explosiveness as the patient returns to sport 1,2 . Rationale: Nonoperative and operative treatment of Achilles tendon rupture can both result in excellent patient outcomes. Appropriate patient selection is critical. Younger patients hoping to return to more highly competitive athletics should consider operative repair 3 . Possible differences have been identified in peak torque when comparing operative versus nonoperative treatment, with patients who had undergone operative repair having greater peak torque (i.e., explosiveness) 2 . Otherwise, findings are similar between treatment options as long as the patients meet the criteria for nonoperative treatment. Expected Outcomes: Overall, the scientific literature demonstrates that the functional outcomes following operative repair are good to excellent. In a study by Hsu et al. 4 , 88% of patients were able to return to their baseline level of activity by 5 months postoperatively, with a complication rate of 10.6% and no reruptures. In a recent meta-analysis by Meulenkamp et al. 5 , the authors found that operative repair of Achilles tendon rupture was associated with a reduced risk of rerupture compared with primary immobilization (i.e., conventional cast immobilization with delayed weight-bearing for at least 6 weeks only). However, open surgical repair, minimally invasive repair, and functional rehabilitation all had similar risk of rerupture 5 . In a review by Ochen et al. 6 that analyzed 29 studies with a total of 15,862 patients, operative repair was associated with a significantly lower risk of rerupture compared with nonoperative treatment (2.3% versus 3.9%, respectively). However, operative treatment was also associated with a significantly higher complication rate compared with nonoperative treatment (4.9% versus 1.6%, respectively) 6 . Finally, in a meta-analysis by Soroceanu et al. 7 , the authors found that if early range-of-motion protocols and functional rehabilitation were utilized, operative and nonoperative treatment resulted in similar outcomes and equivalent rates of rerupture. Important Tips: To prevent rerupture of an Achilles tendon, remind patients to engage in adequate stretching and warming prior to physical activity. Palpate and locate the tendon defect prior to making the first incision. Immobilize the ankle joint in a splint for 2 weeks postoperatively in maximum plantar flexion. Pitfalls include: ○ Poor suture management leading to tangling in the repair. ○ Undertensioning or overtensioning of the repair, which can be avoided by sterilely draping out both legs and checking resting tension intraoperatively. ○ Failure to close the paratenon, causing scarring of the skin or surrounding tissues, which can be avoided by making a relieving incision on the deep surface of the paratenon. ○ Leaving suture knots on the dorsal side of the repair that may aggravate the skin. Acronyms & Abbreviations: MRI = magnetic resonance imaging ESU = electrosurgical unit
Gamut of Extratesticular Scrotal Masses: Anatomic Approach to Sonographic Differential Diagnosis
Gabriel, Helena , Hammond, Nancy A., Marquez, Rocio A., Vendrami, Camila Lopes , Casalino, David D. , Miller, Frank H. , Bhatt, Shweta , Lopes Vendrami, Camila, Horowitz, Jeanne M , Casalino, David D , Nikolaidis, Paul, Miller, Frank H , Bhatt, Shweta , Nikolaidis, Paul

Mayo Clinic

RadioGraphics | March 9, 2023 | Volume: 43 | Issue: 4 | Pages: No page available

10.1148/rg.220113 | PMID 36893051 Get It

Diagnosis of Heart Failure With Preserved Ejection Fraction Relies on Detection of Increased Diastolic Filling Pressure, But How?
Oh, Jae K. , Miranda, William R. , Kane, Garvan C.

Mayo Clinic

Journal of the American Heart Association | March 9, 2023 | Volume: 12 | Issue: 6 | Pages: No page available

10.1161/jaha.122.028867 | PMID 36892047 Get It

Supraorbital Edema as a Predictor of Eyelid Edema Following Neurotoxin Administration
Richey, Patricia M. , Avram, Mathew M., Solish, Danielle, Wanner, Molly, Solish, Danielle , Cotofana, Sebastian

Mayo Clinic

Dermatologic Surgery | March 9, 2023 | Volume: 49 | Issue: 4 | Pages: 433-434

10.1097/dss.0000000000003737 | PMID 36892544 Get It